Intellectual Product
Trump Administration Considers Cuts to CDC’s HIV Prevention Program, Raising Concerns
HIV prevention, CDC funding cuts, Trump administration, public health, HIV/AIDS advocacy
AstraZeneca Inks $1.35B Deal with Alteogen for Subcutaneous Cancer Drugs Amid Industry Patent Disputes
AstraZeneca, Alteogen, subcutaneous cancer drugs, licensing agreement, patent dispute, Merck, Halozyme, hyaluronidase enzyme
Sutro discards CEO, 50% of staff, sole clinical-stage ADC and manufacturing site to save cash
Sutro, therapeutic autologous dendritic cells, Changing, CEO, Cash
Viking Therapeutics Signs $150 Million Manufacturing Deal with CordenPharma for Obesity Drug VK2735
Viking Therapeutics, CordenPharma, VK2735, Obesity drug, GLP-1/GIP dual agonist, Contract manufacturing, API production, Fill/finish capacity, Subcutaneous and oral formulations
Drug Pricing and the Uncertain Future of the IRA Under Trump
IRA, Transplant Registry Unified Management Program, drug price, Medicare, Mediation, repeal, Changing, Uncertainty, Prices
US judge blocks Trump administration from cutting NIH grants amid ongoing litigation
United States National Institutes of Health, Judge, injunction, implementing
Patent Dispute Erupts Over Merck’s Injectable Keytruda
Merck, Halozyme, Keytruda, patent dispute, injectable cancer drug, enzyme technology
UPDATE: DOGE quietly decreases savings estimate for 30 terminated FDA leases
Financial savings, United States Food and Drug Administration, DOGE, Estimated, leases, terminated – RoleStatus, St. Louis, DOGE ‘s
FDA Issues Untitled Letter to NJ Drugmaker for Misleading Cancer Drug Claims at Conference
FDA, untitled letter, misleading promotion, exhibit booth, cancer drug, Edenbridge Pharmaceuticals
Lexicon stumbles on second batch of mixed results for pain drug
Dosage, lexicon, Statistical Significance